Susak Y M, Zemskov V S, Yaremchuk O Y, Kravchenco O B, Yatsyk I M, Korsh O B
Department of General Surgery, Ukrainian State Medical University, Kiev, Ukraine.
Drugs Exp Clin Res. 1996;22(3-5):115-22.
Ninety six colorectal carcinoma patients were included in a randomised study, 48 were treated with Ukrain monotherapy (15 with metastatic and 33 with nonmetastatic colorectal carcinoma) and 48 with 5-fluorouracil (5-FU) and X-ray therapy (the same randomised groups). The results of therapy including clinical, haematological, immunological and biochemical parameters show that Ukrain has favourable properties in the treatment of colon and rectal cancer as a monotherapy because of its malignotoxic and immunomodulating action. Objective response rate in the group of metastatic colorectal cancer treated by Ukrain was 40%. There was no registered tumour regression in the group treated by 5-FU. Operability is strongly facilitated by pretreatment with Ukrain. The survival rate (up to 21 months) in the Ukrain-treated patients with nonmetastatic colorectal cancer was 78.6% and 33.3% in a corresponding control group. Ukrain is a new effective drug in the therapy of colorectal cancer. It can be useful both for the therapy of metastatic colorectal cancer and for neoadjuvant therapy of nonmetastatic colorectal cancer.
96例结肠直肠癌患者被纳入一项随机研究，48例接受乌头碱单一疗法治疗（15例为转移性结肠直肠癌，33例为非转移性结肠直肠癌），48例接受5-氟尿嘧啶（5-FU）和X线治疗（分组相同）。治疗结果包括临床、血液学、免疫学和生化参数表明，由于乌头碱具有抗癌毒性和免疫调节作用，其作为单一疗法在治疗结肠癌和直肠癌方面具有良好特性。乌头碱治疗的转移性结肠直肠癌组的客观缓解率为40%。5-FU治疗组未记录到肿瘤消退情况。乌头碱预处理能显著提高手术可操作性。乌头碱治疗的非转移性结肠直肠癌患者的生存率（长达21个月）为78.6%，相应对照组为33.3%。乌头碱是治疗结肠直肠癌的一种新型有效药物。它对转移性结肠直肠癌的治疗和非转移性结肠直肠癌的新辅助治疗均可能有用。
